Dear Doctor Letter (Rote-Hand-Brief) on Imnovid® (pomalidomide): Information on important aspects of clinical use
2013.08.28
Active substance: pomalidomide
The marketing authorisation holder Celgene is circulating information on important aspects regarding the clinical use of the new medicinal product Imnovid® (pomalidomide).
(SPC-available in German only)
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN